DexCom (DXCM) Stock Forecast & Price Target

DexCom is viewed favorably because it combines a large and expanding total addressable market with differentiated CGM technology, a top-tier management team, and a scalable model that can translate adoption into meaningful volume, revenue, and profit upside even if pricing pressure persists. Its flagship G6 system and ongoing innovation around accuracy, ease of use, connectivity, software, and integration with Insulet and Tandem for automatic insulin delivery reinforce a durable competitive moat, while the early-August introduction of the revamped Stelo app and 15-day wear rollout support broader mainstream adoption and improved user engagement. Fundamental conviction is further strengthened by evidence that CGM can be highly effective beyond intensive insulin users, including the CONNECT results in T2NIT showing broad A1c and TIR improvement, especially strong outcomes across GLP-1, Metformin, and SGLT-2 regimens, and an approximately 97% CGM utilization rate that suggests stronger retention and higher annual revenue per patient than feared.

DexCom is facing a negative outlook because its first-quarter results, while generally solid, still revealed a roughly 1% U.S. growth miss that fueled a bear narrative around a potential U.S. CGM market slowdown, even as worldwide revenue reached $1.19B and U.S. sales of $832M grew 11% but underperformed expectations. The company’s reliance on continued U.S. acceleration tied to CMS T2NIT coverage and the 15-day G7 contribution leaves the investment case exposed if category growth cools, particularly since the paragraphs note that the U.S. market did demonstrate some slowing and that both competitors have not historically captured outsized benefits from each other’s softness. Although margins and cash generation were strong, with adjusted gross margin at 63.5%, adjusted operating margin at 22.2%, adjusted EBITDA margin at 30.6%, and cash and marketable securities of $2.42B, the broader concern is that reiterated 2026 revenue guidance of $5.16B-$5.25B and only modest margin-step improvements suggest the stock may be priced for a more durable reacceleration than the underlying demand trend currently supports.